Once we found PTK2B or LYN overexpression having independent prognostic capacity in cytogenetic IR-AML patients (N = 324), we explored their prognostic capacity in the patient subgroup having non-favorable FLT3/NMP1 combinations (N = 219). This evidence concerns the gene PTK2B and acute myeloid leukemia.